chunk_id int64 1M 11.9M | document stringlengths 3 4.98k | embedding listlengths 384 384 |
|---|---|---|
10,000,200 | Thrombocytopenia occurs frequently in newborn infants with sepsis, but the exact mechanism remains obscure in those infants who do not have evidence of disseminated intravascular coagulation. Since recent work has suggested a possible immune mechanism for thrombocytopenia observed in adults with sepsis, we have investi... | [
-0.04174288734793663,
-0.023814009502530098,
-0.07811229676008224,
-0.009871150366961956,
0.039233848452568054,
0.062103625386953354,
-0.006530805956572294,
0.15151441097259521,
0.028306687250733376,
0.03497730940580368,
-0.03302942216396332,
-0.03389818221330643,
-0.0063529773615300655,
0... |
10,000,201 | Clinical uses of platelets: a review. | [
-0.024784449487924576,
0.010105451568961143,
-0.05792022496461868,
-0.028683720156550407,
-0.08522624522447586,
0.0054480284452438354,
-0.030172079801559448,
0.15693752467632294,
0.06807571649551392,
-0.047469742596149445,
-0.0211049672216177,
0.02072031982243061,
-0.10540101677179337,
0.0... |
10,000,202 | Severe thrombocytopenia delays but does not prevent the occlusion of an arterial prosthesis in rats. | [
-0.0031997503247112036,
0.010180297307670116,
-0.049393195658922195,
-0.034926991909742355,
-0.061611488461494446,
0.027700919657945633,
-0.026240257546305656,
0.07145900279283524,
0.03267473354935646,
0.05231071636080742,
-0.07257643342018127,
0.09323535114526749,
-0.0475568026304245,
0.0... |
10,000,203 | This study shows that experimentally-induced immune thrombocytopenia significantly delayed occlusion of an arterial prosthesis inserted in rat abdominal aorta. Thrombocytopenia was effective when induced several hours or shortly, or even several hours after the insertion of the prosthesis. Maintenance of severe thrombo... | [
-0.005805287044495344,
0.045348361134529114,
-0.026653975248336792,
-0.004953801166266203,
-0.03428861126303673,
-0.0019755300600081682,
-0.015661846846342087,
0.11015604436397552,
0.05572271719574928,
0.050979722291231155,
-0.04167936369776726,
0.0983729213476181,
-0.03202512115240097,
0.... |
10,000,204 | [Role of hormonal disorders in the etiology of polycystic ovary syndrome (Stein-Leventhal syndrome)]. | [
0.011057673022150993,
0.012441092170774937,
-0.0646216943860054,
0.039117924869060516,
-0.0012868078192695975,
0.000013747582670475822,
0.019601736217737198,
0.04083067551255226,
0.05768685042858124,
0.019010744988918304,
-0.07011856883764267,
0.0823681578040123,
-0.021866215392947197,
-0.... |
10,000,205 | Hematopoiesis in the human spleen. | [
-0.0035459790378808975,
0.0537833645939827,
-0.06903556734323502,
-0.017886923626065254,
-0.10188785195350647,
-0.018564652651548386,
0.06202581524848938,
0.0694204643368721,
0.015921175479888916,
-0.004943681415170431,
-0.016613787040114403,
0.01734165847301483,
0.006448462605476379,
-0.0... |
10,000,206 | To assess the capacity of the human spleen to function as a hematopoietic organ, spleen mononuclear cells from patients undergoing splenectomy were cultured to assay CFU-E, BFU-E, and CFU-C. Although the peripheral blood from cases of hereditary spherocytosis, Gaucher disease, Thalassemia major, and idiopathic thromboc... | [
-0.10901913791894913,
-0.05707886815071106,
-0.08466220647096634,
-0.036391280591487885,
-0.08230457454919815,
-0.02898685447871685,
-0.0155710494145751,
0.10869348794221878,
-0.012560463510453701,
-0.0027262757066637278,
0.0019812718965113163,
-0.005176636856049299,
-0.005019980948418379,
... |
10,000,207 | Studies on erythrocyte porphobilinogen deaminase and uroporphyrinogen cosynthetase in porphyria cutanea tarda. | [
0.030005255714058876,
0.02370733767747879,
-0.11214425414800644,
-0.03383488208055496,
-0.0012587152887135744,
0.013176020234823227,
0.006578419357538223,
0.010140951722860336,
-0.0015939704608172178,
0.013051414862275124,
0.024333393201231956,
-0.033945176750421524,
-0.12105587124824524,
... |
10,000,208 | The porphyrias: clinical chemistry, diagnosis and methodology. | [
0.09227871894836426,
0.038085587322711945,
-0.04469608888030052,
-0.028951996937394142,
-0.06332872062921524,
-0.042902637273073196,
0.0020529211033135653,
-0.007776589132845402,
0.015781821683049202,
0.011938936077058315,
0.030645376071333885,
-0.06674957275390625,
-0.03557056561112404,
0... |
10,000,209 | Use of phenylbutazone in sports medicine: understanding the risks. | [
0.09012531489133835,
0.021799789741635323,
-0.08346547186374664,
-0.015706384554505348,
0.026232803240418434,
0.08614584058523178,
0.00579172233119607,
0.12839806079864502,
-0.01057429239153862,
0.07449356466531754,
-0.0437479242682457,
0.03446091338992119,
0.0005998194683343172,
0.1529929... |
10,000,210 | Despite the widespread use of phenylbutazone, its safety is still a controversial issue. One example of its toxicity is the fact that phenylbutazone has now replaced chloramphenicol as the most common cause of fatal drug-related aplastic anemia. To evaluate the toxicity of phenylbutazone as it is commonly used in sport... | [
0.05939052253961563,
-0.023679569363594055,
-0.05408565700054169,
-0.04227965697646141,
-0.008960137143731117,
0.052667856216430664,
0.028970232233405113,
0.16470174491405487,
0.036716483533382416,
0.03711196035146713,
-0.06008538603782654,
0.0253620445728302,
-0.00848501268774271,
0.14145... |
10,000,211 | Microspectrofluorimetric estimation of the formaldehyde-induced fluorescence of the developing main pelvic ganglion of the rat. | [
0.044578276574611664,
-0.1610070914030075,
-0.04220146685838699,
0.010158986784517765,
0.020462071523070335,
-0.05159267410635948,
0.03479141369462013,
0.02116585150361061,
0.06654065102338791,
0.10382434725761414,
0.026335235685110092,
-0.0025062216445803642,
-0.08306031674146652,
0.10015... |
10,000,212 | The formaldehyde-induced fluorescence (FIF) of the cytoplasm of individual developing neurons of the main pelvic ganglion was recorded microspectrofluorimetrically in order to follow changes in catecholamine (noradrenaline) content during development. For each ganglion, the fluorescence intensity profile was estimated ... | [
0.035679735243320465,
-0.09591282904148102,
-0.0412805899977684,
0.010326441377401352,
-0.030662041157484055,
0.029645361006259918,
0.019185295328497887,
-0.0011045841965824366,
0.0217832550406456,
0.13089007139205933,
-0.006051990203559399,
0.010128523223102093,
-0.06336493790149689,
0.08... |
10,000,213 | [Interaction with completely fluctuationally opened base pairs is not the only pathway for formaldehyde reaction with DNA]. | [
-0.006429887842386961,
-0.021742332726716995,
-0.024655763059854507,
0.018577342852950096,
0.037017785012722015,
-0.006623198743909597,
-0.0952121913433075,
0.007459314540028572,
0.012277742847800255,
0.03109152428805828,
0.032759107649326324,
0.037585750222206116,
-0.08189568668603897,
0.... |
10,000,214 | Onycholysis secondary to toluene sulfonamide formaldehyde resin used in a nail hardener mimicking onychomycosis. | [
-0.14471513032913208,
-0.05687443166971207,
-0.04232269898056984,
0.0029895715415477753,
-0.03932419419288635,
-0.03481309860944748,
-0.021480342373251915,
0.013366539031267166,
-0.019517619162797928,
-0.022070014849305153,
0.00524322222918272,
0.059806108474731445,
-0.037677329033613205,
... |
10,000,215 | Kinetics of hydrolysis of methenamine. | [
0.017725467681884766,
-0.05071725323796272,
-0.003598265117034316,
-0.020449135452508926,
0.037576790899038315,
-0.03449561819434166,
0.031692180782556534,
0.03862069919705391,
0.01669352315366268,
0.0479634627699852,
-0.018433459103107452,
-0.004930452443659306,
-0.006800128612667322,
0.0... |
10,000,216 | The kinetics of degradation of methenamine were studied in citrate--phosphate buffers between pH 2.0 and 7.4 at 37.5 degrees. GLC was used to monitor the rate of hydrolysis. The conversion of methenamine to formaldehyde was found to be pH dependent in the buffers of constant ionic strength, with the reaction half-life ... | [
0.006765143480151892,
-0.051221370697021484,
0.010814894922077656,
-0.04337975010275841,
0.07193567603826523,
-0.04572641849517822,
0.01347710657864809,
0.04334866255521774,
0.045956801623106,
0.1022595688700676,
-0.05580424144864082,
0.006987753789871931,
0.009839409030973911,
0.067725487... |
10,000,217 | Release of serotonin from human platelets in vitro by radiographic contrast media. | [
0.07164152711629868,
-0.007373009342700243,
-0.02133900485932827,
-0.01487181056290865,
-0.0535171777009964,
0.05482294782996178,
-0.011128882877528667,
0.09093920886516571,
0.057371798902750015,
-0.010642318055033684,
-0.001729946001432836,
0.02147614024579525,
-0.11660061776638031,
0.042... |
10,000,218 | Both ionic and nonionic, monomeric and dimeric contrast media were found to release serotonin from intact human platelets in vitro. The monomeric contrast media were compared at the concentration range of 25 mg I/ml. Iothalamate was the strongest and the statistically equal metrizamide iopamidol, and P-297 were the wea... | [
0.02230576053261757,
-0.06923721730709076,
0.008550956845283508,
-0.023553909733891487,
-0.03221674636006355,
-0.02138344570994377,
-0.004840789828449488,
0.131483256816864,
0.0967419296503067,
0.03643123432993889,
-0.018895037472248077,
-0.005920967552810907,
-0.04233850538730621,
0.09962... |
10,000,219 | Relationship between formaldehyde-related antibodies and cross-reacting anti-N-like antibodies in patients undergoing chronic haemodialysis. | [
-0.015803951770067215,
-0.07577729225158691,
-0.006889794021844864,
0.021324103698134422,
-0.044553205370903015,
-0.04881076514720917,
0.026465509086847305,
0.011900579556822777,
0.026210704818367958,
-0.06273462623357773,
-0.07157822698354721,
0.05022100359201431,
-0.06727652996778488,
0.... |
10,000,220 | An attempt was made to determine the sequence of events leading to the production of two distinct antibodies in patients with chronic renal failure who regularly undergo haemodialysis with formaldehyde-resterilizable dialysis units by Multipoint (UK) or Cordis (USA). A distinct pattern emerged-namely, the production of... | [
-0.07039855420589447,
-0.08113966137170792,
-0.06112412363290787,
-0.009241601452231407,
-0.06891664117574692,
-0.03293021768331528,
0.027601808309555054,
0.08006182312965393,
0.041980188339948654,
-0.039048921316862106,
-0.09600541740655899,
0.06585423648357391,
-0.05219428613781929,
0.00... |
10,000,221 | [Hygienic evaluation of phenol-formaldehyde construction materials used for building agricultural structures]. | [
-0.03098803199827671,
-0.018245970830321312,
0.016214653849601746,
-0.00011925675062229857,
0.0976099818944931,
-0.04008570313453674,
-0.02285030297935009,
-0.016325727105140686,
0.0029052526224404573,
0.0398939847946167,
0.001816177973523736,
-0.030012410134077072,
-0.07965990900993347,
0... |
10,000,222 | N-Nitroso compounds from reactions of nitrite with methylamine. | [
0.009625598788261414,
-0.029080547392368317,
-0.02814897522330284,
-0.058612000197172165,
0.019407887011766434,
0.01893818937242031,
0.029097937047481537,
-0.020514342933893204,
0.042516592890024185,
-0.014828601852059364,
-0.0360722616314888,
-0.0222075954079628,
-0.013467835262417793,
0.... |
10,000,223 | [Disinfection and sterilization of artificial pulmonary ventilation apparatus]. | [
-0.02270212210714817,
0.04709286615252495,
-0.05159921199083328,
-0.08176697790622711,
-0.043050769716501236,
-0.06017192453145981,
-0.027457360178232193,
0.04242938384413719,
-0.021505257114768028,
0.06233870983123779,
0.035053376108407974,
0.05031310394406319,
0.022517308592796326,
0.069... |
10,000,224 | Stability of formalin test solutions. | [
-0.10366052389144897,
-0.012162819504737854,
0.024841638281941414,
0.009348706342279911,
0.03546347841620445,
-0.028073348104953766,
-0.005574043374508619,
0.03226647153496742,
-0.03644871711730957,
0.005043158307671547,
0.0030241122003644705,
-0.02697695605456829,
-0.0579439215362072,
0.0... |
10,000,225 | The role of the macrophage in in vitro primary anti-DNP antibody production in man. | [
-0.007282686419785023,
-0.01831352524459362,
0.027567680925130844,
-0.0671510323882103,
-0.010233759880065918,
-0.067861407995224,
0.052280277013778687,
0.06780099868774414,
-0.04384107142686844,
0.10921565443277359,
-0.11593852937221527,
0.012695164419710636,
-0.09613516926765442,
0.02380... |
10,000,226 | Combined autoradiography and formaldehyde-induced fluorescence methods for localization of radioactively labeled substances in relation to monoamine neurons. | [
0.09253350645303726,
-0.082855224609375,
-0.06061384081840515,
-0.021275078877806664,
0.050915930420160294,
0.029063932597637177,
0.06270234286785126,
0.00737418420612812,
0.02073827013373375,
0.11740482598543167,
0.04065193608403206,
0.011870852671563625,
0.02688330039381981,
0.1323001384... |
10,000,227 | A combined technique of formaldehyde-induced fluorescence (FIF) and autoradiography is described for the localization of radioactively labeled substances in relation to monoamine neurons. This method permits the simultaneous visualization of 3H-labeled steroid hormone or drug uptake sites and fluorescing monoamine neur... | [
0.09246876835823059,
-0.06680610030889511,
-0.07420144975185394,
-0.029208997264504433,
0.04998971149325371,
0.0185218695551157,
0.009197898209095001,
-0.003133150050416589,
0.03643376752734184,
0.13675056397914886,
0.042932573705911636,
-0.033483054488897324,
-0.048848021775484085,
0.1061... |
10,000,228 | Formaldehyde sensitivity and toxicity. | [
0.03457726538181305,
-0.02861817367374897,
-0.00855365488678217,
0.06117041036486626,
0.09763414412736893,
0.004002945963293314,
0.019399777054786682,
0.06661771237850189,
-0.028331613168120384,
0.04328346624970436,
-0.00934693869203329,
-0.002927243011072278,
-0.04801247641444206,
0.07582... |
10,000,229 | Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. | [
0.03147825226187706,
-0.08704258501529694,
0.05027104169130325,
-0.020289892330765724,
0.04168418422341347,
-0.0011291604023426771,
-0.027579035609960556,
0.153502956032753,
0.09929253160953522,
-0.05739804729819298,
-0.013460090383887291,
-0.0804508849978447,
-0.01719675213098526,
0.11772... |
10,000,230 | The kinetics of ceftriaxone, a cephalosporin, was studied in six healthy subjects who received bolus injections of 150, 500, and 1,500 mg intravenously in a random crossover fashion. Although total drug concentration time profiles after all doses could be described by biexponential equation, simple compartment analysis... | [
0.09043993055820465,
-0.048884905874729156,
0.025579333305358887,
-0.08148711174726486,
0.005540715996176004,
-0.07399415224790573,
-0.01127766165882349,
0.2303742617368698,
0.10412756353616714,
-0.09086281061172485,
0.004199022892862558,
-0.07085740566253662,
0.05416121333837509,
0.101249... |
10,000,231 | Paradoxical sleep deprivation and performance of an active avoidance task: impairment of c57BR mice and no effect in c57BL/6 mice. | [
0.04333722963929176,
0.014914530329406261,
0.03688116744160652,
0.12432032078504562,
0.01145947352051735,
0.13615548610687256,
0.009197456762194633,
-0.015576444566249847,
-0.014066560193896294,
0.03794664144515991,
-0.11042451113462448,
-0.01107016671448946,
0.03530959412455559,
-0.008076... |
10,000,232 | [Comparative study of Faust et al. and Ritchie methods for parasitological examinations of feces]. | [
0.08498704433441162,
0.0361642949283123,
-0.0536968968808651,
-0.02757055126130581,
-0.03142130747437477,
0.032532624900341034,
-0.039732661098241806,
0.09561880677938461,
-0.055925387889146805,
-0.014802822843194008,
0.007919828407466412,
0.009157291613519192,
-0.0046059610322117805,
0.04... |
10,000,233 | A monoclonal antibody-inhibiting FMLP-induced chemotaxis of human neutrophils. | [
-0.00383834564127028,
-0.007787005975842476,
-0.05181359499692917,
0.018657024949789047,
-0.05747860297560692,
-0.02493925578892231,
-0.029939476400613785,
0.08977650105953217,
0.09979764372110367,
-0.02485186606645584,
0.0057871295139193535,
-0.030300484970211983,
-0.004121365956962109,
0... |
10,000,234 | A monoclonal IgG1 antibody, termed NCD3, was raised against human neutrophils and has been shown to inhibit neutrophil chemotaxis. NCD3 displayed a considerable degree of stimulus specificity in that it inhibited N-formyl-methionyl-leucyl-phenylalanine- (FMLP) induced chemotaxis up to 80%, C5a and zymosan-activated pla... | [
-0.061880361288785934,
-0.07376588135957718,
-0.04780910536646843,
0.02094423584640026,
0.04609791561961174,
-0.00582402478903532,
-0.0160882119089365,
0.09842626750469208,
0.10856477916240692,
0.011958641931414604,
-0.038569215685129166,
-0.013621826656162739,
0.047767333686351776,
0.0926... |
10,000,235 | An introduction to current controversies in cancer management: stage I testicular cancer-a case in point. | [
0.006481811869889498,
0.034723322838544846,
-0.05964941158890724,
-0.020502673462033272,
0.03898528963327408,
-0.03340538963675499,
0.06640991568565369,
-0.004328524228185415,
0.03539975732564926,
0.07164712995290756,
0.034256771206855774,
0.11897601932287216,
0.04391663521528244,
0.058892... |
10,000,236 | Optimal management of clinical stage I nonseminomatous testicular carcinoma: one oncologist's view. | [
0.01731974072754383,
0.04652392491698265,
-0.0806422084569931,
0.0016151071758940816,
-0.008994312025606632,
-0.10128304362297058,
0.02170649543404579,
0.0374022014439106,
0.08212872594594955,
0.032241273671388626,
0.018742553889751434,
0.0685230940580368,
0.04400419816374779,
0.0257543046... |
10,000,237 | Prophylactic antimetastatic treatment with aryldimethyltriazenes as adjuvants to surgical tumor removal in mice bearing Lewis lung carcinoma. | [
-0.0000926644352148287,
0.04859009012579918,
-0.04584746062755585,
-0.0031603877432644367,
-0.0639692023396492,
-0.02758239023387432,
0.1008903980255127,
-0.006664580199867487,
-0.03714129701256752,
0.02715982310473919,
-0.011034552939236164,
0.09406860172748566,
0.03877348080277443,
0.052... |
10,000,238 | The effects of two benzenoid dimethyltriazenes (1-p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt [DM-COOK] and 1-p-tolyl-3,3-dimethyltriazene), which have been previously shown to reduce the formation of spontaneous lung metastases in mice bearing subcutaneous Lewis lung carcinoma, have been investigated in mic... | [
-0.021143434569239616,
0.06863603740930557,
-0.01781700737774372,
-0.049018412828445435,
-0.050041988492012024,
-0.01256575994193554,
0.02969781495630741,
0.08986537158489227,
0.030880790203809738,
-0.0025477767921984196,
-0.005515372846275568,
0.033284272998571396,
0.03704932704567909,
0.... |
10,000,239 | Doxorubicin cytotoxicity enhanced by local anesthetics in a human melanoma cell line. | [
0.016673361882567406,
0.023881273344159126,
-0.01620853878557682,
0.012424477376043797,
-0.027410898357629776,
-0.05799539014697075,
0.011506655253469944,
0.12979860603809357,
0.11140387505292892,
-0.00008941996202338487,
-0.07957824319601059,
0.007536600809544325,
0.058910198509693146,
0.... |
10,000,240 | Local anesthetics may influence cell membrane structure and permeability. An established human melanoma cell line (SHG) derived from malignant ascites was used to evaluate the growth-inhibitory effects of local anesthetics (procaine and lidocaine) as well as of doxorubicin at incubation temperatures of 37.5 degrees C a... | [
0.03737889230251312,
-0.02241089753806591,
-0.07363081723451614,
0.021873822435736656,
-0.0186374019831419,
-0.020344793796539307,
0.025629175826907158,
0.11517372727394104,
0.09679795801639557,
0.018510974943637848,
-0.04850778356194496,
-0.000144891906529665,
0.07057187706232071,
0.05204... |
10,000,241 | Adsorption of antineoplastic drugs following large-volume ip administration to rats. | [
0.04689621552824974,
0.005588596221059561,
0.06084815040230751,
0.000496384222060442,
-0.006307107396423817,
-0.0775349885225296,
0.10484806448221207,
0.08580002188682556,
0.019257746636867523,
-0.016423145309090614,
-0.023584559559822083,
0.14721669256687164,
0.04915672540664673,
0.025573... |
10,000,242 | Clinical stage I testis tumors: the medical oncologist's view. | [
-0.012067633680999279,
0.07888773828744888,
-0.0830245316028595,
-0.06794174760580063,
-0.01095298957079649,
-0.1411816030740738,
0.03724013268947601,
0.056614458560943604,
0.11050403863191605,
0.07764432579278946,
-0.04105205461382866,
0.06685712933540344,
0.03190651163458824,
0.013570447... |
10,000,243 | Local and systemic toxicity resulting from large-volume ip administration of doxorubicin in the rat. | [
0.06263849884271622,
-0.0471615269780159,
-0.031994499266147614,
-0.011921612545847893,
-0.004365017171949148,
-0.05319475382566452,
0.012505615130066872,
0.14932763576507568,
0.12749791145324707,
-0.06000617519021034,
0.000346140906913206,
0.06938107311725616,
0.05009152367711067,
0.13282... |
10,000,244 | Doxorubicin was administered to rats in a simulated "belly bath" protocol. Fifty milliliters of various concentrations of drug solution was administered ip and was allowed to remain in situ for either 4 or 36 hours prior to removal. Animals were analyzed at 2, 14, and 60 days after treatment. Doses ranged from lethal (... | [
0.09390578418970108,
-0.05855106562376022,
0.008679206483066082,
0.008809229359030724,
-0.07135831564664841,
-0.0914020836353302,
-0.020188387483358383,
0.16176223754882812,
0.10313821583986282,
-0.03962963819503784,
0.0034024929627776146,
0.07632990181446075,
0.053109146654605865,
0.15189... |
10,000,245 | Combination chemotherapy with cyclophosphamide, vincristine, and prednisone (CVP) in TNM-classified stage IV mycosis fungoides. | [
-0.011732833459973335,
0.08658528327941895,
-0.028218625113368034,
-0.08107258379459381,
-0.07723577320575714,
-0.08571241050958633,
-0.013727783225476742,
0.1289835423231125,
0.027033090591430664,
0.08907566964626312,
0.014218729920685291,
0.019794564694166183,
0.07832677662372589,
0.0686... |
10,000,246 | Nine patients with stage IV mycosis fungoides (MF), according to TNM classification, were treated with cyclophosphamide, vincristine, and prednisone (CVP). CVP induced a 66% overall objective response rate and a 44% complete response rate, which is the highest reported in the literature. CVP is an effective regimen in ... | [
0.005295853596180677,
0.09185338020324707,
-0.03539492189884186,
-0.04773949831724167,
-0.02957245707511902,
-0.07430776953697205,
0.008568283170461655,
0.14353324472904205,
-0.00010278338595526293,
0.06370394676923752,
0.022016748785972595,
-0.0062703960575163364,
0.09296772629022598,
0.1... |
10,000,247 | Phase II study of divided-dose vinblastine in non-small cell bronchogenic carcinoma. | [
0.07013887912034988,
-0.01562665030360222,
-0.053809672594070435,
-0.05163371562957764,
0.012927359901368618,
-0.02026558853685856,
-0.07212484627962112,
0.1190950945019722,
0.04825224727392197,
-0.08031981438398361,
0.0017208964563906193,
0.07292279601097107,
0.1191478744149208,
0.0160066... |
10,000,248 | A role for vinblastine (VBL) in lung cancer has never been clearly defined. Because of recent pharmacokinetic data suggesting a biweekly schedule for VBL and recent antitumor activity shown for vindesine, a phase II trial of divided-dose VBL was initiated. Among 22 evaluable patients, a 27% major response rate was seen... | [
0.03262905031442642,
-0.016097016632556915,
-0.04219219833612442,
-0.05009660869836807,
0.020360054448246956,
0.0002515166124794632,
-0.06942761689424515,
0.13818389177322388,
0.038603998720645905,
-0.040455400943756104,
-0.07447630167007446,
0.11623676866292953,
0.08621539920568466,
0.057... |
10,000,249 | Phase I trial of spirogermanium given by infusion in a multiple-dose schedule. | [
0.02557593397796154,
-0.029344690963625908,
0.001934143016114831,
-0.016642816364765167,
0.02034062147140503,
-0.0004239537811372429,
-0.044617604464292526,
0.09552785754203796,
0.01939733885228634,
-0.004758739843964577,
0.02839132957160473,
0.0461573600769043,
0.075682632625103,
0.047164... |
10,000,250 | In a phase I study of spirogermanium, a new azaspiran-germanium compound, 28 patients were given a multiple-dose schedule. When infused over 1 hour, the maximum tolerated single dose of this agent was greater than 120 mg/m2 but significant chronic neurologic toxicity occurred after 1-2 weeks of treatment. Patients with... | [
0.04663100838661194,
-0.042888183146715164,
-0.06306688487529755,
-0.005733499303460121,
-0.032200250774621964,
0.018565509468317032,
0.0245595034211874,
0.14914648234844208,
0.04294659569859505,
-0.023465802893042564,
0.0455806739628315,
0.02374974824488163,
0.07895582914352417,
0.0863055... |
10,000,251 | Phase II study of doxorubicin and mitomycin in non-small cell bronchogenic carcinoma. | [
0.060479070991277695,
0.0024025337770581245,
-0.047502659261226654,
-0.07004917412996292,
0.029428796842694283,
-0.04339202120900154,
-0.05865443870425224,
0.12947489321231842,
0.10492647439241409,
-0.07868761569261551,
0.05093082785606384,
0.050526805222034454,
0.18177887797355652,
0.0368... |
10,000,252 | Thirty patients with advanced measurable non-small cell bronchogenic carcinoma were treated with a combination of doxorubicin (50 mg/m2 every 3 weeks) and mitomycin (20 mg/m2 every 6 weeks). One complete and three partial responses were observed. This response rate is similar to that reported for either drug used alone... | [
0.09960727393627167,
0.03439433500170708,
-0.049279313534498215,
-0.07388672977685928,
-0.004686936270445585,
-0.08676043152809143,
-0.04393531754612923,
0.1628345400094986,
0.0979699045419693,
-0.08903458714485168,
0.026353588327765465,
0.0641670823097229,
0.1559702605009079,
0.0475637130... |
10,000,253 | Disposition of indicine N-oxide in mice and monkeys. | [
0.00601204251870513,
-0.06351455301046371,
-0.00790578406304121,
0.03111688233911991,
0.057583317160606384,
-0.027910012751817703,
0.004887926857918501,
0.13039450347423553,
0.008495554327964783,
0.007338426075875759,
0.004272966179996729,
0.0961981788277626,
0.008657951839268208,
0.087169... |
10,000,254 | The disposition of tritium-labeled indicine N-oxide (INO) was evaluated in mice and rhesus monkeys. Disappearance of INO from the serum of BDF1 mice given iv doses of 100 or 500 mg/kg occurred with an initial half-life of about 11 mins followed by a second phase greater than 100 mins. At 2 hrs after iv injection of mic... | [
-0.011349992826581001,
-0.03828301653265953,
-0.03642632067203522,
-0.011977230198681355,
-0.01192571222782135,
-0.026767998933792114,
0.030840324237942696,
0.17507220804691315,
0.012198375537991524,
0.020847627893090248,
-0.004365209024399519,
0.039626408368349075,
0.06671389192342758,
0.... |
10,000,255 | Phase II trial of mitolactol in patients with metastatic melanoma. | [
0.034138381481170654,
-0.018065908923745155,
-0.01579011045396328,
0.018467042595148087,
0.03915691748261452,
-0.014297332614660263,
-0.0667482241988182,
0.08730553835630417,
0.0070436554960906506,
-0.012604985386133194,
0.0441405326128006,
-0.054972101002931595,
-0.002785162767395377,
0.0... |
10,000,256 | Combination chemotherapy for bronchogenic carcinoma with doxorubicin, BCNU, and cyclophosphamide (ABC): a pilot study of the Southeastern Cancer Study Group. | [
0.06774299591779709,
0.04990652948617935,
-0.03790665790438652,
-0.13083617389202118,
-0.08600202202796936,
-0.04474721476435661,
-0.029896330088377,
0.10474403202533722,
0.08697625994682312,
-0.044128064066171646,
-0.05060236528515816,
0.006065906025469303,
0.13796275854110718,
-0.0235224... |
10,000,257 | Prednimustine in advanced soft tissue sarcomas. | [
-0.034159474074840546,
0.01556768361479044,
-0.015931710600852966,
0.009468002244830132,
-0.04991469159722328,
-0.04931569844484329,
0.05301791802048683,
0.035111863166093826,
0.021090738475322723,
0.06426513940095901,
-0.027934212237596512,
0.04932952672243118,
0.0497836209833622,
0.05884... |
10,000,258 | Phase II study of high-dose intermittent cycloleucine in colorectal malignancies. | [
0.03706049546599388,
-0.04998673126101494,
0.011691738851368427,
-0.0036186599172651768,
-0.034693922847509384,
-0.0963970273733139,
-0.04532615467905998,
0.08248976618051529,
0.0615762434899807,
-0.08235273510217667,
-0.042108189314603806,
0.049214333295822144,
0.10094493627548218,
0.0160... |
10,000,259 | Is there a relation between previous tuberculosis and long-term survival after solid tumor chemotherapy? | [
0.014999902807176113,
0.00024070480139926076,
-0.04916718602180481,
-0.09466066211462021,
0.011616886593401432,
0.02062297612428665,
-0.0419568233191967,
0.11308594048023224,
-0.01706499420106411,
-0.04317377507686615,
-0.04659726098179817,
0.1111588403582573,
0.14190292358398438,
0.011312... |
10,000,260 | Proper analysis of clinical trials for malignant glioma. | [
-0.034942179918289185,
0.057176508009433746,
-0.01528006698936224,
-0.05992401763796806,
-0.07026585191488266,
-0.0665673092007637,
-0.006054152734577656,
0.038217149674892426,
0.0441027395427227,
0.0041001481004059315,
0.003224399872124195,
0.015409184619784355,
-0.0425829216837883,
-0.05... |
10,000,261 | Elevation of plasma antidiuretic hormones (ADH) associated with chemotherapy-induced emesis in man. | [
-0.005048827733844519,
0.02261325716972351,
-0.05176740512251854,
-0.007004354149103165,
-0.033212073147296906,
-0.07751826196908951,
0.0643138512969017,
0.08938080817461014,
0.0028188112191855907,
-0.007108632475137711,
-0.027955589815974236,
0.03931797668337822,
0.010384744964540005,
-0.... |
10,000,262 | Eleven randomly hydrated patients with metastatic malignancies received iv bolus chemotherapy. Serial observations of plasma antidiuretic hormone (ADH), serum osmolality, blood pressure, and presence of nausea or emesis were made over the next 3-4 hours. Group 1 (four patients) had no nausea or emesis and no change in ... | [
0.03758419305086136,
-0.014767112210392952,
-0.034656696021556854,
-0.007066171150654554,
0.03367317095398903,
-0.1382683962583542,
0.025464937090873718,
0.12069465965032578,
0.047837238758802414,
-0.07312268018722534,
-0.02628585882484913,
0.018661273643374443,
0.05092019587755203,
-0.063... |
10,000,263 | Nonparametric confidence limits for survival probabilities and median survival time. | [
-0.013251496478915215,
-0.038098834455013275,
0.0008770422427915037,
-0.021873611956834793,
0.11739549785852432,
-0.03238532692193985,
-0.06446392089128494,
0.10422058403491974,
0.042904265224933624,
-0.004632195457816124,
0.035022322088479996,
-0.059350233525037766,
0.00794560182839632,
-... |
10,000,264 | Comparison of the use of teniposide and vincristine in combination chemotherapy for non-Hodgkin's lymphoma. | [
-0.013862947933375835,
-0.013118015602231026,
-0.027094364166259766,
-0.11606955528259277,
-0.033594004809856415,
0.010055708698928356,
-0.009676866233348846,
0.17361314594745636,
0.0832681879401207,
-0.036803245544433594,
-0.0059972479939460754,
0.1259748786687851,
0.028335293754935265,
0... |
10,000,265 | A total of 164 patients with non-Hodgkin's lymphoma (NHL) were randomized to receive cycles of treatment every 3 weeks with either CTP, ie, cyclophosphamide (400 mg/m2/day orally X 5), teniposide (VM-26) (100 mg/m2 iv X 1), and prednisolone (60 mg/m2/day orally X 5), or COP, ie, vincristine (1.4 mg/m2 iv X 1; maximum, ... | [
0.024953743442893028,
0.045760802924633026,
0.024390503764152527,
-0.10409910976886749,
-0.0671645775437355,
-0.011316902935504913,
-0.002081263577565551,
0.14251147210597992,
0.046721018850803375,
0.03303707763552666,
-0.05764581263065338,
0.10192865133285522,
0.07316581904888153,
-0.0063... |
10,000,266 | Surgical treatment of clinical stage I nonseminomatous germ gell tumors of the testis. | [
-0.015696046873927116,
0.11351163685321808,
-0.059052132070064545,
-0.03420078009366989,
-0.035476766526699066,
-0.09806770086288452,
0.0931691899895668,
0.04302598163485527,
0.08538670092821121,
0.03814317286014557,
0.03250370919704437,
0.04366307705640793,
0.03489683195948601,
0.04866498... |
10,000,267 | The rationale for further treatment after orchiectomy and the logical basis of the principle therapeutic alternatives in the management of clinical state I nonseminomatous germ cell tumors of the testis have been reviewed. Retroperitoneal lymph node dissection provides the epitome of staging accuracy and a high degree ... | [
-0.024595877155661583,
0.12140873074531555,
0.002092906041070819,
-0.04714452847838402,
-0.030903847888112068,
-0.09700147062540054,
-0.03643583133816719,
0.043303363025188446,
0.07958685606718063,
0.050415489822626114,
0.050654880702495575,
0.07307718694210052,
0.02560833841562271,
0.0114... |
10,000,268 | Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report. | [
-0.01093023456633091,
-0.04126616194844246,
-0.012930137105286121,
-0.0673067569732666,
0.03258587047457695,
-0.07786357402801514,
-0.04905613511800766,
0.11071939766407013,
0.049342915415763855,
0.02150949090719223,
-0.007347249425947666,
0.06636407226324081,
0.03828129172325134,
0.053456... |
10,000,269 | Fifteen patients with advanced stage D hormone-resistant prostate cancer were treated with the combination of doxorubicin, mitomycin, and 5-FU. Nine patients (60%) had objective responses, with a mean duration of 27.9 weeks. No responding patient had relapsed. Although three patients developed a culture-negative leukop... | [
0.028846830129623413,
0.0014772199792787433,
0.007607866544276476,
-0.0787758007645607,
0.014686103910207748,
-0.07931165397167206,
-0.06474436819553375,
0.16002525389194489,
0.0704137310385704,
0.0014414195902645588,
-0.07263720780611038,
0.04606291651725769,
0.05572298541665077,
0.044184... |
10,000,270 | Methyl-GAG in patients with malignant neoplasms: a phase I re-evaluation. | [
0.07927978038787842,
0.028339169919490814,
-0.053180065006017685,
-0.044493820518255234,
-0.03458818048238754,
-0.027780158445239067,
0.030512645840644836,
0.027860542759299278,
0.045839808881282806,
-0.0644218772649765,
-0.00029859913047403097,
0.005761133506894112,
0.02360016666352749,
-... |
10,000,271 | Methyl-GAG was given to 71 patients with advanced malignancies as a weekly brief infusion (30-120 minutes) or as a biweekly 24- or 120-hour infusion. Mucositis (stomatitis, pharyngitis, esophagitis, and, rarely, inflammation of other mucous membranes) was dose-limiting in all three schedules. Generalized fatigue, malai... | [
0.10700798779726028,
-0.005400107707828283,
-0.03278765082359314,
-0.0410655252635479,
-0.03996735438704491,
-0.07303277403116226,
0.0322737917304039,
0.16070738434791565,
0.05030056834220886,
-0.038630466908216476,
-0.05931580811738968,
-0.0016059400513768196,
0.08788875490427017,
0.02111... |
10,000,272 | Phase I study of L-alanosine using a daily x 3 schedule. | [
0.0022261198610067368,
-0.08656559139490128,
-0.027117157354950905,
-0.01552010141313076,
0.02089228853583336,
0.015104281716048717,
-0.07401703298091888,
0.091158926486969,
0.014710938557982445,
0.0050507159903645515,
-0.019208870828151703,
0.02544679306447506,
-0.014486500062048435,
0.03... |
10,000,273 | L-Alanosine is an antitumor antibiotic that inhibits adenine synthesis. It showed significant activity in animal tumor systems. Using a daily x 3 dose schedule every 3 weeks, we performed a phase I study to determine toxicity in man. Doses of 8-375 mg/m2/day x 3 were administered to 49 patients in 117 courses. The dose... | [
0.09645906835794449,
-0.04066190868616104,
0.008308938704431057,
-0.046792976558208466,
-0.030400475487113,
-0.050924841314554214,
0.027376635000109673,
0.09701041132211685,
0.06173522397875786,
0.02550908923149109,
-0.03615465387701988,
0.006279527675360441,
0.06368116289377213,
0.0394347... |
10,000,274 | Pilot study of PALA and 5-FU in patients with advanced cancer. | [
0.06966425478458405,
-0.025156719610095024,
0.007837506011128426,
-0.011601736769080162,
-0.03127916157245636,
-0.042414236813783646,
-0.04134657606482506,
0.026241177693009377,
0.042420875281095505,
0.04477551579475403,
0.007917686365544796,
0.02162996679544449,
-0.09238126128911972,
0.00... |
10,000,275 | A pilot study was carried out among 21 patients with advanced solid tumors to establish appropriate dose levels of PALA and 5-FU given on a 5-day schedule to produce definite but tolerable clinical toxicity. While dermatitis, diarrhea, leukopenia, and thrombocytopenia were observed, stomatitis was the dose-limiting sid... | [
0.04926363378763199,
-0.013885081745684147,
-0.021478857845067978,
-0.06743492931127548,
-0.09595334529876709,
-0.02007296495139599,
-0.012677773833274841,
0.10821516811847687,
0.04626470431685448,
0.06865696609020233,
-0.05031541734933853,
0.04381650313735008,
-0.02769847959280014,
0.0283... |
10,000,276 | Phase I trial and pharmacokinetics of a daily x 5 schedule of 3-deazauridine. | [
-0.010070930235087872,
-0.052511073648929596,
-0.04453311115503311,
0.026452144607901573,
-0.0480978898704052,
-0.05910979211330414,
0.015467412769794464,
0.024442175403237343,
-0.026801401749253273,
-0.04926648736000061,
0.0049850819632411,
0.04075359180569649,
-0.023271210491657257,
0.04... |
10,000,277 | The uridine analog 3-deazauridine has been given to 19 patients in a phase I and pharmacokinetic study. Only mild toxicity was seen at doses less than 1200 mg/m2/day for 5 days. At a dose of 1200 mg/m2/day x 5, leukopenia (mean wbc count nadir of 2650/mm3) was seen in nine of 12 patients and thrombocytopenia (mean plat... | [
0.013132046908140182,
-0.027971766889095306,
-0.06340919435024261,
-0.03121970221400261,
-0.10689982026815414,
-0.09475909918546677,
0.01412584912031889,
0.17587494850158691,
0.0078655406832695,
-0.012808612547814846,
-0.035431765019893646,
0.03266918286681175,
-0.014791355468332767,
0.089... |
10,000,278 | Effect of malnutrition on methotrexate toxicity and tissue levels of dihydrofolate reductase in the rat. | [
0.04077156260609627,
-0.04879719391465187,
-0.030147651210427284,
0.0593046136200428,
-0.03908045217394829,
0.01579499989748001,
0.05297321081161499,
0.11268417537212372,
-0.07208550721406937,
-0.05924045667052269,
-0.10018127411603928,
0.002430936321616173,
-0.018169350922107697,
-0.01840... |
10,000,279 | The effect of malnutrition on the toxicity of methotrexate (MTX) and the dihydrofolate reductase (DHFR) content of the liver, small intestinal mucosa, kidney, and bone marrow of male Sprague-Dawley rats was studied. Malnutrition was induced by reducing the daily intake of chow to one third for 14 days. A single ip trea... | [
0.06050192937254906,
0.008955898694694042,
0.008192583918571472,
0.09152732789516449,
-0.054441191256046295,
0.0033303883392363787,
0.024880709126591682,
0.09741942584514618,
-0.05305331572890282,
-0.06632906198501587,
-0.06688307225704193,
-0.009180471301078796,
0.0070271799340844154,
-0.... |
10,000,280 | Vinylogous carbinolamine tumor inhibitors. 8. Activity of bis(acyloxymethyl) derivatives of pyrroles and pyrrolizines against a panel of murine leukemias and solid tumors. | [
-0.0039995769038796425,
0.05069931223988533,
-0.01817839778959751,
-0.054783895611763,
-0.10884251445531845,
0.1037038266658783,
0.06371092051267624,
0.052039675414562225,
0.07498166710138321,
0.010397713631391525,
-0.028360120952129364,
0.013916341587901115,
-0.043610863387584686,
-0.0332... |
10,000,281 | The activity of three pyrroles and four pyrrolizines is compared in several different experimental leukemias and solid tumors in mice. Two compounds were particularly noteworthy, the bis(N-cyclohexylcarbamate) and the bis[N-(2-propyl)] derivatives of 2,3-dihydro-5-(3,4-dichlorophenyl)-6,7-bis(hydroxymethyl)-1H-pyrroliz... | [
0.0066180904395878315,
-0.036217689514160156,
0.014275715686380863,
-0.0713464692234993,
-0.03791464865207672,
0.02984265610575676,
0.07171259075403214,
0.021845120936632156,
0.0864795446395874,
0.006047376431524754,
-0.05735928192734718,
0.04088245704770088,
-0.003394570667296648,
-0.0107... |
10,000,282 | Pulmonary blood volume ratio response to exercise; a noninvasive determination of exercise-induced changes in pulmonary capillary wedge pressure. | [
-0.01727328449487686,
0.028277872130274773,
-0.00343419355340302,
0.019611507654190063,
-0.007001171819865704,
0.02365802973508835,
-0.034143876284360886,
0.020553303882479668,
-0.02468261681497097,
-0.01235930621623993,
-0.04880737513303757,
-0.03510931879281998,
-0.010652059689164162,
0.... |
10,000,283 | Independent contribution of electrocardiographic abnormalities to risk of death from coronary heart disease, cardiovascular diseases and all causes. Findings of three Chicago epidemiologic studies. | [
0.0637463927268982,
0.05883532389998436,
0.028501562774181366,
0.030862804502248764,
0.06750134378671646,
0.0023125330917537212,
-0.04567889869213104,
0.06638723611831665,
-0.013482633978128433,
-0.009059068746864796,
0.04570366442203522,
-0.05212722346186638,
-0.010917509905993938,
-0.020... |
10,000,284 | Epicardial activation in patients with coronary artery disease: effects of regional contraction abnormalities. | [
0.08816059678792953,
-0.042526040226221085,
0.0030522961169481277,
0.0578627735376358,
-0.01233555469661951,
0.021389193832874298,
-0.042315978556871414,
-0.0031746237073093653,
0.08569774031639099,
-0.022294500842690468,
0.032243452966213226,
0.02640082687139511,
-0.016217978671193123,
0.... |
10,000,285 | Intramyocardial conduction: a major determinant of R-wave amplitude during acute myocardial ischemia. | [
0.009370476007461548,
-0.05591992661356926,
0.06023067235946655,
0.0793970599770546,
0.057128556072711945,
-0.01778915710747242,
-0.030342452228069305,
0.08999194949865341,
0.005508770234882832,
0.01967618055641651,
-0.0477135144174099,
-0.0019029841059818864,
0.000711096334271133,
0.10884... |
10,000,286 | Two-dimensional echocardiographic features of right ventricular infarction. | [
0.03193063288927078,
0.012023157440125942,
0.01481027901172638,
0.03614489734172821,
0.04589641094207764,
0.00806915108114481,
-0.10890129208564758,
-0.030399084091186523,
-0.002029869006946683,
-0.11304724216461182,
0.03640232980251312,
-0.05765175819396973,
-0.0891813114285469,
0.0364984... |
10,000,287 | Real-time, two-dimensional echocardiographic studies were performed in 10 patients with acute myocardial infarction who had clinical features suggestive of right ventricular involvement. All patients showed right ventricular wall motion abnormalities. In the four-chamber view, seven patients showed akinesis of the enti... | [
0.045931629836559296,
0.009628038853406906,
-0.009187238290905952,
-0.03260679170489311,
0.02061351016163826,
-0.04622273147106171,
-0.11380743235349655,
0.04041868820786476,
0.05626809597015381,
-0.0955844521522522,
0.015551936812698841,
-0.06849633902311325,
-0.008654328063130379,
0.0586... |
10,000,288 | Verapamil versus placebo in relieving stable angina pectoris. | [
0.04050706699490547,
-0.027534326538443565,
-0.04630519449710846,
0.05145477131009102,
-0.0040583424270153046,
-0.03479068726301193,
-0.09498488157987595,
0.01000752579420805,
0.07453213632106781,
-0.08794012665748596,
0.004241246730089188,
0.07439914345741272,
-0.06343346834182739,
0.0290... |
10,000,289 | Verapamil and placebo were compared in patients with stable, effort-induced angina. Single-blind dose titration (240, 360 and 480 mg/day) preceded a double-blind crossover. Among the 18 patients who completed graded exercise stress tests with reproducible pretreatment effort-limiting angina, exercise duration increased... | [
0.06938084959983826,
-0.034507591277360916,
-0.009236964397132397,
0.07904317229986191,
-0.040817007422447205,
-0.025003882125020027,
-0.026390593498945236,
0.06601107865571976,
0.03927848860621452,
-0.06350333243608475,
-0.042272355407476425,
0.027913551777601242,
-0.052712082862854004,
0... |
10,000,290 | Evaluation of combined valvular prolapse syndrome by two-dimensional echocardiography. | [
0.06119835376739502,
-0.016607418656349182,
-0.030194658786058426,
-0.015433699823915958,
-0.05047459155321121,
-0.01635308563709259,
-0.036464594304561615,
0.048864636570215225,
0.036294419318437576,
-0.10980263352394104,
0.010809116065502167,
0.053504325449466705,
-0.03601537272334099,
-... |
10,000,291 | The patterns of aortic and tricuspid valve motion in 50 patients with mitral valve prolapse were analyzed by wide-angle, phased-array, two-dimensional echocardiography. Twelve patients (24%) had redundant aortic leaflets bulging into the left ventricular outflow tract during diastole. Eight of 12 patients had aortic re... | [
0.03727063536643982,
-0.041351620107889175,
-0.0731712132692337,
-0.09453370422124863,
0.03176348656415939,
-0.0027412218041718006,
-0.030765727162361145,
0.016763249412178993,
0.036148883402347565,
-0.05007786676287651,
0.0743541494011879,
0.0172318946570158,
0.023125939071178436,
-0.0423... |
10,000,292 | Arterial dilators in mitral regurgitation: effects on rest and exercise hemodynamics and long-term clinical follow-up. | [
0.07186683267354965,
-0.013585023581981659,
0.06391830742359161,
-0.040555257350206375,
-0.03755628317594528,
-0.014619186520576477,
-0.10944459587335587,
0.007366740610450506,
0.039334334433078766,
-0.06128193810582161,
0.06066209822893143,
0.026966741308569908,
0.004957408178597689,
0.03... |
10,000,293 | Determinants and clinical significance of jugular venous valve competence. | [
0.024472489953041077,
-0.016639186069369316,
-0.0695529356598854,
-0.0618814155459404,
-0.021881677210330963,
0.043240517377853394,
0.017922382801771164,
0.08075253665447235,
-0.012956500053405762,
-0.06680125743150711,
-0.003061724826693535,
-0.045172907412052155,
-0.00894390232861042,
0.... |
10,000,294 | We studied the function of right internal jugular vein valves during cardiac catheterization in 32 patients and external jugular vein valves in vitro from 13 dogs. Patients with normal central venous pressure had competent valves during cough-induced transvalvular pressure gradients of 52.4 +/- 8.6 mm Hg. Ten of 15 pat... | [
-0.005472209304571152,
-0.01590055041015148,
-0.0738552138209343,
-0.0439392514526844,
-0.033828165382146835,
0.011256991885602474,
-0.03288307413458824,
0.04893616959452629,
0.05933341756463051,
-0.04884559288620949,
-0.001969879260286689,
-0.04649277403950691,
0.0408133901655674,
0.07445... |
10,000,295 | Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man. | [
0.03993520140647888,
-0.046053994446992874,
-0.10974162817001343,
-0.011600058525800705,
-0.03457394242286682,
0.07877609133720398,
-0.000599806837271899,
0.07248371839523315,
0.02432747557759285,
-0.035581108182668686,
-0.04181420058012009,
0.021091246977448463,
-0.07364503294229507,
0.09... |
10,000,296 | Although serious hemorrhage during therapeutic coadministration of sulfinpyrazone and racemic warfarin occurs, no prospective studies have been done. In this study, single oral doses of racemic warfarin, 1.5 mg/kg, were administered to six normal subjects with and without oral sulfinpyrazone, 400 mg daily. Both the hyp... | [
0.003890772582963109,
-0.031691573560237885,
-0.11146891117095947,
-0.003859821241348982,
-0.02835840731859207,
0.07022721320390701,
-0.04348220303654671,
0.16592630743980408,
0.027783168479800224,
-0.010585303418338299,
-0.0722820833325386,
0.05844483524560928,
-0.03811391443014145,
0.095... |
10,000,297 | Secondary prevention in myocardial infarction survivors. | [
0.013916237279772758,
0.05721626430749893,
0.024193355813622475,
0.057866085320711136,
0.10630106180906296,
0.051972728222608566,
-0.06779418885707855,
0.1335873156785965,
0.017078077420592308,
-0.014885862357914448,
0.0188133604824543,
0.02358376979827881,
-0.008577026426792145,
0.0117799... |
10,000,298 | The 24-hour ambulatory blood pressure profile with verapamil. | [
-0.03715740889310837,
0.02112949639558792,
-0.03359726816415787,
0.0642315223813057,
-0.009669178165495396,
-0.00014853831089567393,
-0.06584754586219788,
0.008984504267573357,
0.015801113098859787,
-0.11289811134338379,
0.015021526254713535,
-0.02813994698226452,
-0.05673331394791603,
0.0... |
10,000,299 | The blood pressure response in hypertensive subjects to chronic treatment with verapamil, a calcium antagonist (or, more precisely, a slow-channel inhibitor), was studied using the Oxford system for continuous monitoring of intraarterial blood pressure. Sixteen patients underwent continuous monitoring over a 48-hour pe... | [
-0.005801690276712179,
0.004304156173020601,
0.01621653325855732,
0.0451568104326725,
-0.04315318539738655,
-0.02016964741051197,
-0.07173217833042145,
-0.011961436830461025,
0.03558570146560669,
-0.038769494742155075,
0.02377868816256523,
0.009276586584746838,
-0.02242616005241871,
0.0392... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.